Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

CDMO

 

Motion Equity Partners acquires Polaris

French private equity firm Motion Equity Partners has announced the acquisition of France-based biotech firm Polaris, which produces highly concentrated omega-3 from microalgae.
June 17, 2026

Oxford Biomedica potentially open to private equity offers

UK-based Contract Development Manufacturing Organisation (CDMO) Oxford Biomedica (OXB) may be open to a private equity takeover, provided any offer meets the company's valuation expectations and supports its long-term growth ambitions.
June 17, 2026

CordenPharma acquires AmbioPharm

CordenPharma, a CDMO backed by private equity firm Astorg, has acquired AmbioPharm, a US-headquartered peptide CDMO, from private equity firm Carlyle. 
June 4, 2026

CVC and GBL launch €10.7 bn take-private offer for Recordati

Luxembourg-based private equity firm CVC Capital, through CVC Fund IX, and Belgian investment firm Groupe Bruxelles Lambert (GBL) have launched a €10.7 billion ($12.4 ‌billion) cash offer for all outstanding ordinary shares to take Italian pharmaceutical firm Recordati private. 
May 27, 2026

HBI 2026: How pharma services can maintain scalability and differentiation

The pharma services sector is recovering, but unevenly. Biotech funding has returned to healthy levels, and trial starts are rebounding to previous peak levels. However, geopolitical challenges and AI disruption fears persist.  At HBI 2026, a panel discussed the challenges and opportunities facing the pharma services sector.
April 28, 2026

Everstone Capital invests $270 million in Apothecon Group

Singapore-based private equity firm Everstone Capital has invested around $270 million in Apothecon Group, a specialty pharma Contract Development and Manufacturing Organisation (CDMO). The combined group includes India-based Apothecon and US-based Navinta. Together, they work on complex molecules, mainly in iron and peptide-based chemistry.
April 23, 2026

Polypeptide Group attracts takeover interest from private equity firms

Polypeptide Group, a listed Switzerland-based contract development and manufacturing organisation (CDMO) serving pharmaceutical and biotech companies, has attracted takeover interest from private equity investors. The company specialises in peptide-based active pharmaceutical ingredients (APIs) and operates manufacturing sites across the United States, Europe, and India.
April 16, 2026

SHS Capital exits and reinvests in German speciality pharma AMW GmbH

Healthcare focused private equity firm SHS Capital has exited and reinvested in German speciality pharma company AMW GmbH, as part of a syndicate of investors including specialist investment firm Ren Life Sciences and global investment firm Juno Capital Partners.
March 19, 2026

Navigating the global pharma order in 2026 —in conversation with ING’s Stephen Farrelly and Diederik Stadig

Ahead of the HBI 2026 session ‘The new global pharma order: Trump, China and Europe's uncertain future’, HBI spoke to Stephen Farrelly, Managing Director, Global Lead Healthcare & Pharma at ING and Diederik Stadig, Senior Economist, Healthcare & Pharma at ING on what the future holds for pharma investment and strategy, from regulatory risks and European biopharma's structural challenges to the evolving role of CDMOs, CROs, and the role of private equity.
March 18, 2026

Lone Star buys Lonza’s CHI division for ~$3 billion

Private equity firm Lone Star Funds has acquired the Capsules & Health Ingredients (CHI) division of Swiss Contract Development and Manufacturing Organisation (CDMO) Lonza Group for an enterprise value of CHF 2.3 billion (~$3 billion). Headquartered in Basel, Switzerland, the CHI business manufactures capsules used to deliver medicines and dietary supplements. It operates across the Americas, Europe, and the Asia Pacific. 
March 12, 2026
Older posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us